Popular on Amzeal
- Retrospec Appoints Nick Marvik as New Head of Growth to Lead eCommerce Expansion
- New Book Further Unravels the Myth of a "Chemical Imbalance" Causing Depression
- Connected Technologies Delivers Cutting-Edge Technology to Landmark Properties' Student Housing Communities
- AI pioneer & tech icon, Professor Chris Imafidon speaks on President Trump's $500 Billion AI project
- Enter the Dragon - PermianMuseum.com adds a Winged Dragon Fossil
- How Technology is Making the Florida Court System More Accessible
- LAIIER Closes Oversubscribed US$4M Seed Extension Funding Round, Led by Closed Loop Partners
- The Power Of Online Reviews & Why They Matter
- Osaretin Agbonavbare's AI NGO Makes History at Trump's Presidential Inauguration Ceremony
- Advanced HDR by Technicolor Enables 2024 UEFA Championship's French Broadcast in High Dynamic Range
Similar on Amzeal
- Wide range of dental care products at upto 40% discounted prices | DentistryDeal.com
- NaturismRE, ANF, and GNA Stand United for Naturist Rights in Australia – A Call for Global Support
- Volante of Hanover Expands with the Opening of Its Second Building, Introduces Assisted Living Services
- New Jersey Sober Living Opens New Luxury Themed Facility in South New Jersey
- Hawaii Bill Marks Progress in Protecting Patients From Dangerous Restraint Practices
- Gold Coast Health Plan Distributes $225,000 for Fire Relief and Preparedness Efforts
- Gold Coast Health Plan Among State's Top Performers for Outstanding Health Care Quality
- NC Health Official Urges Ban on Wilderness Therapy Camps Following Child's Death
- $27 Million Funding; Coverage on Sanjay Gupta/CNN for Treatment of Suicidal Depression; Nasdaq Tier Uplisting: NRx Pharmaceuticals: Stock Symbol: NRXP
- New Book Further Unravels the Myth of a "Chemical Imbalance" Causing Depression
The ROS1ders Announce Recipient of Eunice and Milton Ring Grant for ROS1 Cancer Research
Amzeal News/10565291
Patient-founded nonprofit seeks to stimulate innovative research to improve outcomes for patients with ROS1+ cancers.
SACRAMENTO, Calif. - Amzeal -- The ROS1ders announced the recipient of the 2024 Eunice and Milton Ring Grant for ROS1 Cancer Research. Funding for this grant is provided by Eunice and Milton Ring, whose daughter Karen Ring Weiss is a member of the ROS1+ cancer community.
The 2024 award was granted to Anthony Iafrate, MD, Ph.D, Professor of Pathology at Harvard Medical School and Vice Chair of Academic Affairs at the Massachusetts General Hospital. Dr. Iafrate's team is seeking new approaches to targeting ROS1+ fusion cancers that can overcome acquired resistance to current targeted therapies. They aim to identify regions of ROS1 fusion proteins that can be attacked with covalent inhibitors, which may lead to new treatments.
"Patient advocacy calls attention to the need for research about specific cancer biomarkers," says Eunice Ring. "Because ROS1+ cancer is rare, patients and their families must provide leadership in research focused on their cancer. We are very pleased to support Dr. Iafrate's team."
More on Amzeal News
This grant is the third in a series of seed grants focused on ROS1+ cancers. Janet Freeman-Daily, co-founder and president of the ROS1ders, says "Our ROS1+ cancer community is grateful that biomarker testing and targeted therapy have added years to so many lives. However, the currently approved drugs don't work well for everyone. We hope our seed grants will generate findings that lead to larger research efforts and better outcomes."
About the ROS1ders
Founded by patients, The ROS1ders is the largest global group of patients and family members living with ROS1+ cancer. It seeks to improve outcomes for all ROS1+ cancers through community, education, and research. Membership in their private Facebook group exceeds 1,100 people from over 30 countries. The nonprofit is internationally recognized in the oncology and patient advocacy communities as experts in their disease. Its resources include a medically-vetted website and collaboration with international ROS1+ clinicians, researchers and industry. Please visit theros1ders.org to learn more.
More on Amzeal News
About ROS1+ Cancer
The 2024 award was granted to Anthony Iafrate, MD, Ph.D, Professor of Pathology at Harvard Medical School and Vice Chair of Academic Affairs at the Massachusetts General Hospital. Dr. Iafrate's team is seeking new approaches to targeting ROS1+ fusion cancers that can overcome acquired resistance to current targeted therapies. They aim to identify regions of ROS1 fusion proteins that can be attacked with covalent inhibitors, which may lead to new treatments.
"Patient advocacy calls attention to the need for research about specific cancer biomarkers," says Eunice Ring. "Because ROS1+ cancer is rare, patients and their families must provide leadership in research focused on their cancer. We are very pleased to support Dr. Iafrate's team."
More on Amzeal News
- OEM Technology Partnerships Launches Brokerage Specializing in 100+ OEM Technologies
- Cura HR's CEO, Lyssa Hansard, Featured in Forbes: Driving Meaningful Change in Pay Equity
- G2 Names OpenWater a Winter 2025 Leader in Awards and Scholarship Management
- Zezgo Rent A Car has arrived In Cyprus to Improve Car Rental Options
- Meredith Thomas Returns as Master of Ceremonies for International Women's Day Gala for 2025
This grant is the third in a series of seed grants focused on ROS1+ cancers. Janet Freeman-Daily, co-founder and president of the ROS1ders, says "Our ROS1+ cancer community is grateful that biomarker testing and targeted therapy have added years to so many lives. However, the currently approved drugs don't work well for everyone. We hope our seed grants will generate findings that lead to larger research efforts and better outcomes."
About the ROS1ders
Founded by patients, The ROS1ders is the largest global group of patients and family members living with ROS1+ cancer. It seeks to improve outcomes for all ROS1+ cancers through community, education, and research. Membership in their private Facebook group exceeds 1,100 people from over 30 countries. The nonprofit is internationally recognized in the oncology and patient advocacy communities as experts in their disease. Its resources include a medically-vetted website and collaboration with international ROS1+ clinicians, researchers and industry. Please visit theros1ders.org to learn more.
More on Amzeal News
- Kim Estes Returns as Master of Ceremonies for International Women's Day Gala for 2025
- Andre Kay Honored with Black Excellence Award by the Florida Panthers
- Media Advisory Pastor Mark Burns to Deliver Remarks at BEYA Stars and Stripes Dinner What: The BEYA Stars and Stripes
- Wide range of dental care products at upto 40% discounted prices | DentistryDeal.com
- NaturismRE, ANF, and GNA Stand United for Naturist Rights in Australia – A Call for Global Support
About ROS1+ Cancer
- ROS1+ cancer is relatively rare, occurring in just 1-2% of non-small cell lung cancer (NSCLC). The incidence is thought to be similar in other types of cancer.
- Biomarker testing for ROS1 fusions is recommended in guidelines for non-small cell lung cancer, but currently for few other cancers.
- Patients are typically younger than the average NSCLC patient, have adenocarcinoma, and have no smoking history (a smoking history should not exclude patients from biomarker testing or targeted therapies).
- Oral targeted therapies are the recommended first-line treatment for metastatic ROS1+NSCLC and have increased the survival of patients by years. However, these drugs eventually stop working due to acquired resistance. The mechanisms of resistance are not well understood.
Source: The ROS1ders
0 Comments
Latest on Amzeal News
- Uhland Pop Shop Launches February 11, 2025, Bringing Local Pride to Uhland, TX
- Nova Health Labs Welcomes New Advisory Board Members to Drive Patient-Centered Innovation
- C-BATT joins NAATBatt, the premier US Battery Trade Association
- Partnerships to Launch Digital Entertainment Hub in China; $40 Million Investment into Global MOBA Digital Game Arena: NIP Group (Stock Symbol: NIPG)
- Sip Social Co. Brings Refreshing Energy to the Miami Marathon Finish Festival with FP Movement
- Igniting Souls® and EOS Worldwide® Launch EOS Impact™: The Exclusive Publishing Collaboration for 850+ EOS Implementers
- Ceramic Liberty Unveils CL8Y: A Revolutionary Deflationary Memecoin Set to Redefine DeFi
- International Women's Day Gala to Celebrate Women's Achievements and Support Fire Survivors
- Sidow Sobrino Unleashes Bite After Bite, a Captivating Music Video & Song from His 12th Studio Album, Seminal
- How New U.S. Tariffs Are Reshaping the Frequency Control & Precision Timing Industry
- L-Tron welcomes Senator Pam Helming to their Victor, NY Office
- PCnet Supports Business Growth with Reliable Managed IT Services
- New Jersey Sober Living Opens New Luxury Themed Facility in South New Jersey
- Atlanta Students to Talk with Astronauts on International Space Station
- Hawaii Bill Marks Progress in Protecting Patients From Dangerous Restraint Practices
- All me - secure anonymous social - kickstarter crowdfunding
- HomeFortis Launches Target Hardening Guides for Home Security
- Retired Leadership Facilitator Shares Decades of Wisdom in New Book
- CCG Relaunches Spring Virtual Recruitment Fair to Connect Employers with Top STEM, AI, and Veteran Talent
- The AI Revolution: How ChatGPT-Like Tools Will Transform Industries by 2030